Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of IBI354 Neoadjuvant Monotherapy in HER2-Expressing Advanced Epithelial Ovarian Cancer
ChiCTR2500104920Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IBI354 in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: R0 resection rate. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
IBI354
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2500104920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104920.